NEO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NeoGenomics Inc. (NEO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown revenue growth, its declining net income, EPS, and gross margin, along with neutral insider and hedge fund trading trends, suggest caution. The technical indicators are neutral, and there are no strong proprietary trading signals or significant positive catalysts to justify immediate action. Holding or waiting for further developments is recommended.
The MACD is positive at 0.0754 but contracting, indicating a lack of strong momentum. The RSI is neutral at 42.489, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 8.12, with resistance at 8.605 and support at 7.635.
NeoGenomics has integrated its oncology testing portfolio with the Epic Aura system, which could enhance clinical decision-making and streamline processes.
Declining net income (-35.52% YoY), EPS (-33.33% YoY), and gross margin (-2.43% YoY) in the latest quarter. No significant insider or hedge fund trading trends. No recent congress trading data.
In Q4 2025, revenue increased by 10.56% YoY to $190.17M. However, net income dropped by 35.52% YoY to -$9.88M, EPS fell by 33.33% YoY to -$0.08, and gross margin decreased by 2.43% YoY to 43.83%.
Piper Sandler raised the price target from $12 to $13 and maintained an Overweight rating, reflecting a positive outlook but not a strong buy signal.
